Introduction
Primary immunodeficiency disorders constitute a group of hereditary diseases characterized by abnormality of host-defense mechanisms. The prognosis in patients affected with such disorders is poor. Allogenic BMT offers the chance to establish a new donor-derived immune system, thereby reversing this poor prognosis. It was first successful in the treatment of a patient with lethal primary immunodeficiency diseases just after the major human histocompatibility system (HLA) was discovered in 1968. 1, 2 In that year, immune function was conferred on two children with primary immunodeficiency diseases (Wiskott-Aldrich Syndrome and X-linked severe combined immunodeficiency) by transplanting into them unfractionated HLA-identical sibling bone marrow cells. Since that time, transplantation has gained an increasingly fundamental role in the management of these disorders. Importantly, this kind of treatment can be applied for a broad spectrum of patients, with less restricted donor selection including unrelated and HLA-mismatched family donors.
Materials and methods
We reviewed the pediatric hematology/oncology database for the unit from 1993 to 2006. We did not exclude causes of death unrelated to the SCT procedure. The primary immunodeficiency disorder in our community, which is almost 20 times more common than the published data incidence of such disorder, is due to high consanguinity marriage. 3 For the same reason, the majority of our SCT is through HLA-matched related donors (Figures 1 and 2) . The majority of patients had SCID, which represents a lymphocyte disorder, either a developmental or differentiation defect ( Table 1 ). The second group of diseases comprised the MHC antigen deficiency syndrome (bare lymphocyte syndrome). The third large group is the Wiskott-Aldrich syndrome; the fourth group is a functional defect of intracellular pathogen-killing phagocytic cells (chronic granulomatous disease) or migration adhesion defect (LAD), and the last group constitutes cytotoxic function defects (Griscelli and Chediak-Higashi syndromes). Most congenital immunodeficiencies are due to monogenetic defects, and in the majority the molecular basis has been clarified in recent years. Understanding of the molecular mechanism has many implications, in particular, for more precise classification and prenatal diagnosis, as well as for prognosis. It has also opened the possibility of novel treatment by gene manipulation. 4, 5 SCID constitutes a major as well as serious immunodeficiency characterized by complete lack of specific immune functions. Diagnosis is considered a medical emergency because of the tendency to rapidly develop fatal infections, which cannot be overcome without effective immune function. SCID is not a single disorder but rather a group of distinct genetic entities. Before identification of the underlying genetic abnormalities, the various SCID forms were distinguished on the basis of differences in phenotype and function of the lymphocyte and whether inheritance was autosomal recessive or X-linked, as well as the presence or absence of an accompanying enzyme deficiency. Immunophenotype of blood lymphocyte to main forms is delineated with an autosomal recessive inheritance characterized by an absence of T and B lymphocytes. The second is associated with both X-linked autosomal recessive mode of inheritance characterized by an absence of T cells but the presence of nonfunctioning B cells. In our institute, we recently started to look for genetic mutation in all varieties of SCID. Our pediatric immune disorder SCT program had a steady increase in cases due to increasing awareness of the disease, which led to an increase in bed allocations for each category of disease ( Figure 3) . Stem cell transplants due to pediatric immune disorders constituted 24% (196/807) of all pediatric stem cell transplants (malignant and nonmalignant) (Figure 4 ).
Results

SCID
Of 110 transplanted patients with SCID (99 fully matched, 7 unrelated cords, and 4 TCD transplantations), the percentage of survival based on the type of transplantations was 80, 71, 50%, respectively, and we thought that this percentage of survival could be improved upon if SCT were performed earlier ( Figure 5 ).
MHC antigen immunodeficiency syndromes
This group included 35 cases transplanted in our institute, 34 cases of HLA-matched SCT and 1 case that received an unrelated cord transplantation. The data in Table 1 indicate a higher success rate compared with others based on the international literature on this disease; the survival percentage was 80% in our institution. We have had only one unsuccessful case of unrelated cord transplantation. A subgroup HLA-matched SCT (6 cases) received reduced intensity conditioning due to preexisting chronic lung disease. Our initial observation showed that this patient was engrafted well initially, but most patients are currently unstable and declined the chimera. SCID  110  99  80  7  71  4  50  BLS  35  34  80  1  0  --WAS  14  10  100  4  50  --LAD  7  6  83  1  100  --CGD  9  7  86  2  100  --Griscelli  9  7  86  2  100  --CHS  6  5  40  1  0%  --HIGM  1  1  100  ----CID  2 
Wiskott-Aldrich syndrome
This is the third largest group of immunodeficiency undergoing BMT in our institution. The first case of transplant was in 1984 and he is still alive. Compared with the survival rate internationally, 6 we had a 100% success rate for 10 fully matched cases, and 50% for 4 cases of unrelated cord transplantations.
Griscelli and Chediak-Higashi syndromes
These two syndromes are characterized by partial albinism and immunodeficiency. If such syndromes are not transplanted, patients will develop fatal lymphoproliferative complications. In our institution, we transplanted 9 Griscelli syndromes, 7 full matches with 86% survival and 2 unrelated cord SCT with 100% survival, 6 cases of Chediak-Higashi syndrome, 5 full matches and 1 unrelated cord transplantation (URCT) with 40% and 0% survival, respectively.
Leukocyte adhesion deficiency
Lymphocyte adhesion deficiency is a disease affecting both PMNs as well as lymphocytes. The presentation of the disease is due to a defect in migration and signaling cooperation with other cells. We transplanted 7 cases, and 5 of 6 survived post-full-match SCT, whereas 1 received an unsuccessful URCT.
Chronic granulomatous disease
This is the last group and not all cases have been transplanted. We transplanted 9 cases; 6 of 7 survived with good stable chimerism post-full-match SCT and 2 of 2 survived after unrelated cord transplantation.
Other primary immunodefiencies
Three cases were transplanted, with one case of X-linked CD40L hyper-IGM syndrome being successful. The CD40 ligand was restored and he is well and alive with good stable donor cells and there were two unsuccessful cases of undetermined combined immunodeficiency.
Conclusion
Clearly, allogenic bone marrow transplant has been a lifesaving and life-extending procedure for many patients with primary immunodeficiency disorders. The most important fact in this field over the past two decades was the discovery that the haploidentical donor could be used for infants with SCID and other immunodeficiency diseases except for the Wiskott-Aldrich syndrome, which can be treated by MUD or an unrelated cord transplant. Bone marrow transplantation will continue to be the treatment of choice for these lethal defects until gene therapy is perfected. Our overall survival is almost 76%, with 24% mortality, which indicates that bone marrow transplantation is not a perfect treatment ( Figure 6 ). The risk of death from infections and GVHD post-SCT preclude its use for patients with only Bcell defects such as XLA, but such individuals can survive many years by intravenous immunoglobulin replacement therapy and prophylactic antibiotic therapy. Gene-modified, autologous BMT can circumvent the complications of current therapy if the limitations associated with the use of gene therapy and the safety of this novel therapy is overcome.
